The Budget Impact of Orphan Drugs in the US: A MIDAS Sales Data Analysis
|
|
- Marvin Hunt
- 6 years ago
- Views:
Transcription
1 The Budget Impact of Orphan Drugs in the US: A MIDAS Sales Data Analysis December 8, 2014 Oral Presentation at the 56th ASH Annual Meeting and Exposition, Session: 902. Health Services and Outcomes Research Malignant Diseases: New/Refined Prognostic Schemes/Pharmacoeconomics Victoria Divino 1 *, Mitch Dekoven, MHSA 1 *, Weiying Wang, MPH 2 *, Michael Kleinrock, MA 1 *, R. Donald Harvey, PharmD 3, Rolin L. Wade, RPh,MS 1 * and Satyin Kaura, MSci, MBA 4 * 1 IMS Health, Fairfax, VA; 2 MKTXS, Raritan, NJ; 3 Winship Cancer Institute, Emory University, Atlanta, GA; 4 Celgene, Summit, NJ
2 Background Study Background The United States (US) Orphan Drug Act (ODA) of 1983 established incentives for the development of drugs that treat rare or orphan diseases. Approximately 25-30M Americans, or 8-10% of the US population, have one of the diseases defined as rare, and thus may benefit from the ODA. 1 The ODA has been successful in stimulating orphan drug development to treat a variety of previously underserved conditions. Despite the clinical value of orphan drugs, payer sensitivity to orphan drugs is increasing due to the perceived potential impact on payers drug budgets. Despite these payer concerns, little evidence/data has been generated as to the actual burden of orphan drug expenditures in the US. Figure 1. Orphan Drug Designations/Approvals Rare Diseases and FDA Perspectives from the Office of Orphan Products Development (OOPD) Presented by Katherine Needleman, MS, PhD, RAC, Director, Orphan Products Grants Program FDA/OOPD at the IRDiRC Conference, April 16 & 17, Handfield R, Feldstein J. Insurance companies' perspectives on the orphan drug pipeline. Am Health Drug Benefits Nov;6(9):
3 Objectives Study Objectives To measure the total annual expenditures on branded orphan drugs between in the US. The specific objectives were: To estimate total orphan drug expenditures in the US from , and to evaluate total orphan drug expenditures as a proportion of total pharmaceutical expenditures. To evaluate future orphan drug expenditures ( ) and as a proportion of total future pharmaceutical expenditures. 3
4 Overview Methods Overview This analysis utilized the US FDA Orphan Drug Product designation website to identify the comprehensive list of drugs which have been approved by the FDA and given orphan status in the US since the establishment of the ODA (1983) through the end of 2013 (N=365 unique products). Only branded products (N=356) were considered in this analysis. The IMS Health MIDAS database was used to assess orphan drug and total drug expenditures in the US between o IMS MIDAS is the gold standard for audited biopharmaceutical sales, a unique analysis tool and on-line system, and the benchmark measure in the industry. IMS MIDAS integrates and extends the IMS Health building blocks that are the IMS National Audits which measures sales volume at the product pack level. The primary analysis focused on expenditures for 291 out of the total 356 (82%) total orphan drugs that were orphan only, approved for a single orphan designation only or for multiple orphan only designations. In a secondary analysis, expenditures for 65 out of the total 356 (18%) orphan drugs, identified as partial orphans, approved for both orphan and non-orphan indications, were adjusted. Utilizing several US sources, in-depth research was conducted in order to determine a disease factor to apply to those sales so only orphan indication sales were considered in the analysis. o The Cowen and Company Equity Research Health Care Therapeutic Categories Report, manufacturers audited financial reports, an analysis of US physician office claims data, the diagnosis value in MIDAS, epidemiology in the US. 4
5 Analyses Analyses Total expenditures for the branded orphan drugs, measured in the MIDAS dataset, were calculated annually from Orphan only drug expenditures were reported for the primarily analysis. Additionally, adjusted partial orphan drug expenditures, and adjusted total orphan drug expenditures (orphan only + partial orphan drugs) were reported. Orphan drug expenditures were further evaluated as a proportion of total annual US pharmaceutical drug expenditures sourced from MIDAS. Expenditures were recorded at the time of the sale. All expenditures were adjusted to 2014 USD using the Bureau of Economic Analysis GDP deflator. Trends in total orphan drug expenditures were assessed over time (e.g. major therapeutic category of orphan indications). A future trend analysis was evaluated (via 2 methods) to estimate orphan drug sales from Future estimated orphan drug sales were evaluated out of projected future total drug sales based on IMS Health Market Prognosis forecasts. 5
6 Orphan Drug Expenditures Results Table Orphan Drugs Captured # Orphan only drugs captured N=252 # Partial Orphan drugs captured N=64 # Total Orphan drugs captured N=316 Orphan Only Drug Expenditures ($) Total Drug Expenditures ($) % Orphan Only / Total Drug Measure Partial Orphan Drug Expenditures ($) 1,724,112,665 2,000,120,316 2,269,512,397 2,981,964,166 3,312,563,575 3,637,321,362 4,204,897,912 Total Orphan Drug Expenditures ($) 15,029,971,619 17,067,138,132 19,394,965,957 23,094,548,844 26,124,999,476 28,030,524,508 30,048,066,281 % Orphan Only / Total Orphan 88.5% 88.3% 88.3% 87.1% 87.3% 87.0% 86.0% % Partial Orphan / Total Orphan 11.5% 11.7% 11.7% 12.9% 12.7% 13.0% 14.0% % Partial Orphan / Total Drug 0.5% 0.6% 0.7% 0.9% 0.9% 1.1% 1.2% % Total Orphan/ Total Drug 4.8% 5.5% 6.0% 6.8% 7.5% 8.5% 8.9% Orphan Only drugs = orphan drugs approved for a single orphan designation only or for multiple orphan only designations. Partial Orphan drugs = orphan drugs approved for both orphan and non-orphan indications, adjusted to include only orphan indication expenditures. Total Orphan drugs = ( Orphan Only drugs + adjusted Partial Orphan drugs) Table Orphan Only Drug Expenditures (2014 USD) ,305,858,954 15,067,017,816 17,125,453,561 20,112,584,678 22,812,435,902 24,393,203,146 25,843,168, ,384,270, ,104,657, ,774,764, ,551,781, ,473,406, ,083,171, ,442,018, % 4.9% 5.3% 5.9% 6.6% 7.4% 7.7% Table Partial Only and Total Orphan Drug Expenditures
7 Results Figure Orphan Drug Expenditures out of Total US Drug Expenditures 4E+11 $311.4B $310.1B $324.8B $340.6B $346.5B $330.1B $337.2B Total Pharmaceutical Expenditure 3.5E+11 3E E % 0.6% 4.3% 4.9% 0.7% 5.3% 0.9% 0.9% 5.9% 6.6% 1.1% 1.2% 7.4% 7.7% Partial Orphan (Adjusted) 2E E+11 1E+11 5E % 94.5% 94.0% 93.2% 92.5% 91.5% 91.1% Orphan Only Non-Orphan (Adjusted) Orphan Only drugs = orphan drugs approved for a single orphan designation only or for multiple orphan only designations. Partial Orphan drugs = orphan drugs approved for both orphan and non-orphan indications, adjusted to include only orphan indication expenditures. Total Orphan drugs = ( Orphan Only drugs + adjusted Partial Orphan drugs) 7
8 Results Oncology was the most common therapeutic class, with 101 (32.0%) out of the total 316 orphan drugs identified with an orphan oncology indication $35.0B 35,000,000,000 Figure Orphan Drug Expenditures by Therapeutic Class $30.0B 30,000,000,000 $25.0B 25,000,000,000 $20.0B 20,000,000,000 $15.0B 15,000,000,000 $10.0B 10,000,000,000 $5.0B 5,000,000,000 $0 - $30.0B $26.1B $28.0B 62.0% 59.3% $23.1B 64.7% $19.4B 66.5% $15.0B $17.1B 68.7% 67.7% 70.7% 40.7% 38.0% 35.3% 33.5% 32.3% 29.3% 31.3% All Other Oncology- Related 8
9 Future trends ( ) suggest a slowing down in orphan drug growth 9 Results Methodology #1: A linear trend line was created using sales Orphan drug expenditures of $33.5- $44.2B, were estimated for , representing % of total U.S. drug expenditures. Methodology #2: Linear trend lines were created to estimate number of orphan drug approvals and average cost in based on data. Future costs were estimated as the number of new approvals x the average cost per drug, added to prior total year orphan drug sales, for each year Orphan drug expenditures of $34.9- $54.9B were estimated for , representing % of total US drug costs. IMS Health Market Prognosis recently forecasted US total drug sales of $380.8-$465.0B.
10 Discussion Discussion While a select few orphan drugs may have high costs, the population using these orphan drugs is small, and total orphan drug expenditures, when considered out of total drug expenditures, is relatively minimal. For the primary analysis of 252 orphan only drugs, expenditures represented % of total US drug sales. Adjusted drug expenditures for 64 partial orphan drugs represented % of total US drug sales between o Our disease factoring analysis suggests that the majority of unadjusted partial orphan drug sales are for non-orphan indications. Following adjustment, orphan indication costs were minimal and represented only % of total unadjusted partial orphan drug expenditures in , respectively. Total orphan drug expenditures represented % of total US drug expenditures, in Future trend analysis suggests that while orphan drug expenditures in will increase, there will be a slowing down in growth, and growth will remain fairly stable as a proportion of total drug expenditures. 10
11 Limitations There are a number of limitations to note with this analysis. Discussion MIDAS database coverage is limited with respect to certain products and/or manufacturers. o The forecasted total drug expenditures from IMS Market Prognosis provide more comprehensive estimates. As our MIDAS estimates may be underestimated due to coverage limitations, our future trend analysis of orphan drug expenditures out of total forecasted drug sales may be further underestimated. Finally, there is the potential for off-label use of orphan drugs. Because the sales data do not have indications associated with sales, it is unknown if, or to what extent, these drugs are being used for off-label indications. 11
12 Conclusions Discussion The ODA has led to an increase in the number of approved orphan drugs, and while associated orphan drug expenditures have increased, these drugs benefit many people with previously underserved rare conditions. The annual expenditures on orphan drugs are small relative to total pharmaceutical drug expenditures. Orphan drug expenditures have remained fairly stable as a proportion of total pharmaceutical expenditures and future trend analysis suggests growth is slowing down. Concerns that growth in orphan drug expenditures may lead to unsustainable drug expenditures do not appear to be justified. 12
Orphan Drugs-The Reinvention of Specialty Pharmacy?
Orphan Drugs-The Reinvention of Specialty Pharmacy? Gordon J. Vanscoy, PharmD, MBA, CACP; Chairman & CEO Jonathan Ogurchak, PharmD, CSP; Vice President, Business Operations Doug Gebhard, PharmD, MBA; Vice
More informationNews For Immediate Release
News For Immediate Release Contact: Gary Gatyas IMS Institute for Healthcare Informatics (610) 244-2600 ggatyas@us.imshealth.com IMS Study Forecasts Rebound in Global Spending on Medicines, Reaching Nearly
More informationSpecialty Pharmacy 101
Specialty Pharmacy 101 The Landscape of Specialty Pharmacy Services DATE: October 27, 2011 NAME: TITLE: Clinical Pharmacist, Serve You Agenda Define specialty pharmacy Examine market trends and current
More informationAgenda: Opportunities in Developing Orphan Drug Products. Mukesh Kumar, PhD, RAC
This Seminar is Brought to you by Amarex Clinical Research Washington DC metro area A Product Development Services Company From Lab to Market Approval FDA Meetings Global Regulatory Submissions Global
More informationCommunicating Emerging Drug Therapies Prior to FDA Approval. May 4, 2017
Communicating Emerging Drug Therapies Prior to FDA Approval May 4, 2017 Michelle Drozd Deputy Vice President, Policy and Research Pharmaceutical Research Manufacturers Association (PhRMA) Michael Labson
More informationInsights into the Rare Disease Drug Approval Landscape: Trends and Current Development
Insights into the Rare Disease Drug Approval Landscape: Trends and Current Development Mike Lanthier Operations Research Analyst FDA Office of the Commissioner NORD Rare Diseases & Orphan Products Breakthrough
More informationACRUX PRESENTS AT BIOSHARES BIOTECH SUMMIT
ACRUX (ACR) - ASX ANNOUNCEMENT 24 JULY 2017 ACRUX PRESENTS AT BIOSHARES BIOTECH SUMMIT Acrux (ASX: ACR) today announced that CEO and Managing Director, Michael Kotsanis presented at the 2017 Bioshares
More informationClarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases
Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration
More informationProgram Coordinator Medication Assistance Program Smilow Cancer Hospital at Yale New Haven
Program Coordinator Medication Assistance Program Smilow Cancer Hospital at Yale New Haven Yale MAP Program Consists of 5 FTE s Has been established for five years Was originally mirrored from the Ohio
More informationPharmacy Benefit Drug Trends and Pipeline. Casey Robinson, PharmD, MBA, Cigna Pharmacy Management
Pharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management Disclosure and Conflict of Interest Dr. Robinson declares no conflicts of interest, real or apparent, and
More informationPharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management
Pharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management Disclosure and Conflict of Interest Pharmacist Objectives Dr. Robinson declares no conflicts of interest,
More informationThe Evolving Regulatory Landscape for Orphan Drugs: FDA Perspectives
The Evolving Regulatory Landscape for Orphan Drugs: FDA Perspectives Debra Lewis, O.D., M.B.A. Acting Director, Office of Orphan Products Development FDLI May 4, 2018 OOPD Core Programs Mission: To promote
More informationHealth Policy Commission 1
Health Policy Commission 1 Topics to be covered 1 Spending trends in Massachusetts and the United States Estimated 13% growth in drug spending in MA in 2014 Substantial growth in top drug classes, in addition
More informationNational Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy
From Hope to Cures: The Value of Biopharmaceutical Innovation National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy HIV/AIDS: Then
More informationGlobal Human Growth Hormones (GH) Drugs Industry. Sizing, Growth and Forecast. Global Human Growth Hormones Deficiency (GHD) Drugs
Global Human Growth Hormones Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential Forecast to 2023 Global Human Growth Hormones (GH) Drugs Industry
More informationPhRMA Days Press Conference
PhRMA Days Press Conference April 12, 2017 Joaquin Duato Chairman of the Board, PhRMA Roadmap I. Recent Developments in the United States II. Biopharmaceutical Industry s Contribution to Innovation and
More informationStrategic vision of Pharma Market
Strategic vision of Pharma Market Evolution 2012-2016 ACIP Presentation, Paris January 30, 2013 Introduction This presentation draws strategic orientations for pharma companies considering the expected
More informationGallagher Healthcare Practice
Gallagher Healthcare Practice Keeping Your Organization in Good Health As the healthcare industry transitions from volume to value, you need a partner with access to a wide set of solutions that can be
More informationThe Evolving Role Of Prescription Benefit Managers
The Evolving Role Of Prescription Benefit Managers Steve Miller, MD Senior Vice President & Chief Medical Officer November 1, 2016 1 Prescription drugs: A growing share of U.S. healthcare spend Net spending
More informationOrphan designation in the EU
Orphan designation in the EU Workshop with Japanese Pharmaceutical Industry 19 September 2013, London Presented by: Jordi Llinares Head of Product Development Scientific Support An agency of the European
More informationTHE BIOPHARMA DILEMMA:
THE BIOPHARMA DILEMMA: Balancing Innovation and Affordability Amitabh Chandra HARVARD UNIVERSITY Disclosures Panel of Health Advisors, CBO Speaking fees from Biogen, Novo Nordisk, Pfizer, PCMA, Roche Consultant
More informationOptimizing Clinical Research Operations with Business Analytics
WHITE PAPER Optimizing Clinical Research Operations with Business Analytics Improving clinical research with analytics Table of Contents The Proven Standard for Clinical Data Analysis...1 Why Clinical
More informationPrecision Medicine & Health Insurance Business Model Disruption? A Data& Evidence perspective
Precision Medicine & Health Insurance Business Model Disruption? A Data& Evidence perspective December 12 th, 2017 Dr. Tim Wintermantel Real World Insights Lead, Switzerland Copyright 2017 IQVIA. All rights
More informationORPHAN DESIGNATION BY THE EMA. Paillard Juliette M2 AREIPS 15/11/2016
ORPHAN DESIGNATION BY THE EMA Paillard Juliette M2 AREIPS 15/11/2016 Legal basis 1. Legal background 2. Criteria SUMMARY Procedure 1. Prior to the submission 2. Submission and validation 3. Evaluation
More information1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Emerging Pharmaceutical Market - Indonesia and the Philippines -Introduction 3 Emerging
1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Emerging Pharmaceutical Market - Indonesia and the Philippines -Introduction 3 Emerging Pharmaceutical Market - Indonesia and the Philippines
More informationDefining Strategic Metrics to Demonstrate Impact
The Value of Medical Affairs: Defining Strategic Metrics to Demonstrate Impact www.envisionpharmagroup.com The Value of Medical Affairs: Defining Strategic Metrics to Demonstrate Impact Objectives Establish
More informationNovember 15, 2011 Louis I. Hochheiser, M.D. Chief Medical Leader
Facilitating Development and Utilization of Genome-Based Diagnostic Technologies: Advancing utility and adoption of clinical genomic diagnostics Part II November 15, 2011 Louis I. Hochheiser, M.D. Chief
More informationOrphan designation in the EU
Orphan designation in the EU EURORDIS summer school Barcelona, June 2013 Presented by: Jordi Llinares Head of Orphan Medicines An agency of the European Union Outline Overview orphan designation Procedure
More informationDefining the true market
Defining the true market Case study: How real-world data and outcomes improved a major pharmaceutical company s launch strategy Cardinal Health Specialty Solutions Competing in a crowded marketplace A
More informationBiotechnology Certificate New Technologies For Health
Weekly Barometer 25 janvier 2012 Biotechnology Certificate New Technologies For Health January 2018 ATONRÂ PARTNERS SA 12, Rue Pierre Fatio 1204 GENEVA SWITZERLAND - Tel: + 41 22 310 15 01 http://www.atonra.ch
More informationUniversity of Connecticut Student Managed Fund 2018 Analyst Report. Jonathan Stryjek & Michael Pehota
University of Connecticut Student Managed Fund 2018 Analyst Report Jonathan Stryjek & Michael Pehota Table of Contents 3 Report Highlights 4 Business Overview 5 Industry Overview and Competitive Positioning
More informationAssessing the Economics of Single-Source vs. Multi-Vendor Manufacturing
Assessing the Economics of Single-Source vs. Multi-Vendor Manufacturing Tufts Center for the Study of Drug Development, Tufts University School of Medicine Boston, MA October 2017 Joseph A. DiMasi, Ph.D.,
More informationDecoding Phase II Clinical Trial Terminations
Decoding Phase II Clinical Trial Terminations Why Phase II trials are terminated and what can be done to improve Phase II success rates - the most critical inflection point for clinical development Subha
More informationInvestor Presentation. October 2018
Investor Presentation October 2018 Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the Private Securities Litigation
More informationGlobal Allied Pharmaceuticals, LLC. Innovation, Research, and Technology. Breaking the bounders, first in its class, thinking outside the box.
Global Allied Pharmaceuticals, LLC. Innovation, Research, and Technology. Breaking the bounders, first in its class, thinking outside the box. The purpose of this presentation Looking for Joint Venture
More informationUniversità Cattolica del Sacro Cuore
Università Cattolica del Sacro Cuore The role of Regulatory Affairs in drug development Francesco Mazza, Director of Legal, Fiscal & Compliance Affairs in Farmindustria Rome, May 12 2017 Who we are Who
More informationDrugs, medical progress,
Drugs, medical progress, and the road ahead Scott Gottlieb, MD Resident Fellow The American Enterprise Institute Page 1 The Pharmaceutical Industry s Market Global Pharmaceutical Sales, by Region (in billions
More informationCENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationSolving the Problem of New Uses
Solving the Problem of New Uses Benjamin Roin, Harvard Law School benroin@law.harvard.edu Presented at Duke Law School Center for Innovation Policy s New Approaches and Incentives in Drug Development,
More informationOptimize Your Medical Affairs Team s Influence in a Start-up Organization
Optimize Your Medical Affairs Team s Influence in a Start-up Organization Rachel Couchenour, PharmD, MBA Sr. Director, Medical Affairs Mateon Therapeutics Objectives Discover the unique challenges faced
More informationThe Blanche and Irwin Lerner Center for the Study of Pharmaceutical Management Issues
The Blanche and Irwin Lerner Center for the Study of Pharmaceutical Management Issues In this issue: Director s Message... Pg. 2 Annual Healthcare Symposium. Pgs. 3-5 Research Publications and Robert E
More informationClinical Trial Methods Course 2017 Trials in Rare Diseases. Erika Augustine, MD, MS University of Rochester Medical Center August 10, 2017
Clinical Trial Methods Course 2017 Trials in Rare Diseases Erika Augustine, MD, MS University of Rochester Medical Center August 10, 2017 Overview Challenges in studying rare diseases Strategies for trial
More informationAccess, Affordability and Innovation Focus on High Cost Medicines: Facts and Potential Options
Access, Affordability and Innovation Focus on High Cost Medicines: Facts and Potential Options Ashoke Bhattacharjya, PhD Robert E Campbell Pharmaceutical Seminar Rutgers Business School Feb 15, 2017 1
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationCompassionate Use: Perspectives from a Patient Advocacy Group
Compassionate Use: Perspectives from a Patient Advocacy Group American Society of Clinical Oncology Annual Meeting 2016 Samantha Roberts, PhD Director of Scientific Affairs, Friends of Cancer Research
More informationRegulatory utilization of Flexible Regulatory Pathways to meet unmet medical need
Median approval time (days) 170 356 Regulatory utilization of Flexible Regulatory Pathways to meet unmet medical need Session: UNMET (MEDICAL) NEED: SHOULD STAKEHOLDERS ALIGN ON A DEFINITION? Neil McAuslane
More informationISSUE BRIEF. Factors Affecting the Growth of Prescription Drugs Expenditures
ISSUE BRIEF FOUNDATION Factors Affecting the Growth of Prescription Drugs Expenditures July 1999 Spending on prescription drugs has increased much more rapidly than spending on other health care services
More informationThe value and specificity of the rare disease business model
The value and specificity of the rare disease business model The point of view from a dedicated orphan drug company Philippe Van Holle International Chairman, Celgene 6th European Conference on Rare Diseases
More informationUS Regulatory and Marketing Barriers for Medical Devices
US Regulatory and Marketing Barriers for Medical Devices September 8, 2015 Zvi Ladin, Ph.D. Principal Boston MedTech Advisors Boston Germany Israel 1 Regulatory Barriers Market Barriers (providers / payers)
More informationIntroduction to the Generic Drug Supply Chain and Key Considerations for Policymakers
Association for Accessible Medicines Introduction to the Generic Drug Supply Chain and Key Considerations for Policymakers Key Takeaways Generic drugs play an important role in the U.S. health care system,
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2018 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationAbstract.
Got value? Determine it. Demonstrate it. Communicate it. Realise it Mitch DeKoven, Elisabeth H. Hazard, Erica Goldberg and Shibani Pokras Received (in revised form): 10th March, 2008 Mitch DeKoven is Director,
More informationPrescription Drug Pricing. Page 1
Prescription Drug Pricing Page 1 Prescription Drugs As a Percent of Total National Health Expenditures, 1991-2014 12% 10% 8% 6% 4% 2% 0% 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
More informationContract Manufacturing of Biosimilars
Contract Manufacturing of Biosimilars Patti Seymour Senior Consultant BioProcess Technology Consultants, Inc. IBC Life Science s Biopharmaceutical Development and Production Huntington Beach, CA February
More informationWhile individually rare, orphan diseases are actually collectively common, with an OF ORPHAN DRUG DEVELOPMENT MEETING THE UNIQUE CHALLENGES
ELECTRONICALLY REPRINTED FROM JUNE 2017 CLINICAL TRIALS Rare Diseases: MEETING THE UNIQUE CHALLENGES OF ORPHAN DRUG DEVELOPMENT BY MICHAEL F. MURPHY, MD, Ph D While individually rare, orphan diseases are
More informationInaugural Fraunhofer Delaware Technology Summit
Inaugural Fraunhofer Delaware Technology Summit Energy and Life Sciences Solu
More informationBiotechnology Certificate New Technologies For Health
Weekly Barometer 25 janvier 2012 Biotechnology Certificate New Technologies For Health April 2017 ATONRÂ PARTNERS SA 12, Rue Pierre Fatio 1204 GENEVA SWITZERLAND - Tel: + 41 22 310 15 01 http://www.atonra.ch
More informationDr. Sanders is a consultant to Accordant Health Services and Jacobus Pharmaceutical Co.
Donald B. Sanders Dr. Sanders is a consultant to Accordant Health Services and Jacobus Pharmaceutical Co. Health care costs for MG & CIDP Financial consequences of the Orphan Drug Act Potential financial
More informationInsights into Rare Disease Drug Approval: Trends and Recent Developments
Insights into Rare Disease Drug Approval: Trends and Recent Developments Mike Lanthier Operations Research Analyst FDA Office of the Commissioner NORD Rare Diseases & Orphan Products Breakthrough Summit
More informationKonica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2018 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationJordi Aparici Market Intelligence Consultant
Jordi Aparici Market Intelligence Consultant Helping pharma companies make robust decisions based on market, competitors and patient knowledge Market Intelligence Strategy Marketing Market Research Data
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2017 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationMedical Pharmacy Trend Report: Managing the Trends and Complexity of Provider- Administered Drugs
Medical Pharmacy Trend Report: Managing the Trends and Complexity of Provider- Administered Drugs Thursday, March 10, 2016 1:00 2:30 EST 12:00 1:30 CST 11:00 12:30 MST 10:00 11:30 PST Casandra Stockman,
More informationJuly 13, Dear Secretary Price:
July 13, 2017 The Honorable Thomas E. Price, M.D. Secretary U.S. Department of Health and Human Services 200 Independence Avenue, SW Washington, DC 20201 Dear Secretary Price: At our meeting on May 16,
More informationSec Short title; finding. Sec Authority to assess and use drug fees. Sec Reauthorization; reporting requirements.
H.R. 2430, FDA Reauthorization Act of 2017 Section 1. Short Title. This Act may be cited as the FDA Reauthorization Act of 2017. Section 2. Table of Contents Table of Contents TITLE I: FEES RELATING TO
More informationHospira at a 5/20/2015. The World s Leading Provider of Injectable Drugs and Infusion Technologies
Sumant Ramachandra, MD, PhD SVP and Chief Scientific Officer Alliance for Health Reform May 20 th, 2015 Hospira at a glance The World s Leading Provider of Injectable Drugs and Infusion Technologies Market
More informationLoxo Oncology Announces Third Quarter 2016 Financial Results
Loxo Oncology Announces Third Quarter 2016 Financial Results November 2, 2016 Updated LOXO-101 Phase 1 Clinical Data Accepted for Oral Presentation at ESMO Asia on December 18, 2016 Company to Provide
More informationLife Sciences Global Capability
Life Sciences Global Capability Integrating ingenuity Through a dedicated team of professionals specialising in investment sales, construction, leasing, facility management, finance and industry specialist
More informationFuture Pharma - Challenges & Trends MES Process & Minds Conference Berlin, Germany, September 2015
Future Pharma - Challenges & Trends MES Process & Minds Conference Berlin, Germany, 28-29 September 2015 (PhD) Agenda Key challenges facing the Pharmaceutical Industry 1. Delivering shareholder/stakeholder
More informationThe Middle East. 15 Countries*, 5 Time Zones. Population > 333 millions** GDP: $3.13 Trillions*** 58% of world oil reserves
Pharmaco-Economical Overview of Healthcare Omar Rifi, R.Ph., M.B.A. January, 2012-1- The Middle East 15 Countries*, 5 Time Zones Population > 333 millions** GDP: $3.13 Trillions*** 58% of world oil reserves
More informationHorizon Scanning for pharmaceuticals
Horizon Scanning for pharmaceuticals EMA Payer Community meeting, Presented by Michael Berntgen Head of Product Development Scientific Support Department An agency of the European Union The foundation:
More informationPersonalized healthcare Getting from promise to reality
Personalized healthcare Getting from promise to reality Severin Schwan, CEO Roche Group Swiss-American Chamber of Commerce, 26 August 2009 1 Roche The challenge Personalised healhcare Implementation at
More informationPresentation at National Academy of Sciences -- Monday, November 14, 2016
Prescription Drug Spending in the U.S.: Is the Era of Slow Growth Over? An Update of an Article with the Same Title in the September 2016 issue of Health Affairs by Murray L. Aitken 1, Ernst R. Berndt
More informationEffect of Biosimilar Development on Global Manufacturing Capacity
Effect of Biosimilar Development on Global Manufacturing Capacity Patti Seymour Senior Consultant BioProcess Technology Consultants, Inc. IBC Life Science s Biopharmaceutical Development and Production
More informationBiomarker Tests for Molecularly Targeted Therapies Key to Unlocking Precision Medicine Report from the National Academy of Medicine
Biomarker Tests for Molecularly Targeted Therapies Key to Unlocking Precision Medicine Report from the National Academy of Medicine Robert Nussbaum MD Chief Medical Officer, Invitae Corporation Former
More informationUsing business intelligence for strategic advantage in REMS Received (in revised form): 23 rd November 2010
Original article Using business intelligence for strategic advantage in REMS Received (in revised form): 23 rd November 2010 Ashwin Mathias is a manager at ZS Associates. He has 8 years of experience in
More informationFDA Driving Biomedical Product Innovation
FDA Driving Biomedical Product Innovation Vicki Seyfert-Margolis, Ph.D. Senior Advisor, Science Innovation and Policy Office of the Commissioner November 12, 2012 1 FDA Mission FDA is charged with protecting
More informationTrends in Weighted Average Sales Prices for Prescription Drugs in Medicare Part B,
Trends in Weighted Average Sales Prices for Prescription Drugs in Medicare Part B, 2007-2017 December 2017 THE MORAN COMPANY 1 Trends in Estimated Average Sales Price for Prescription Drugs in Medicare
More informationAssociate Director of Public Policy, National Organization for Rare Disorders (NORD)
Orphan Drug Act: Paul Melmeyer Associate Director of Public Policy, National Organization for Rare Disorders (NORD) Priority Review Vouchers: Ronald Bartek Co-Founder/Founding President, Friedreich s Ataxia
More informationMarketing Case Studies And Solutions
MARKETING CASE STUDIES AND SOLUTIONS PDF - Are you looking for marketing case studies and solutions Books? Now, you will be happy that at this time marketing case studies and solutions PDF is available
More informationGlobal Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017
Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts (2017-2021) November 2017 Global Contract Research Organization (CRO) Market : Coverage Executive Summary and Scope Introduction/Market
More informationDIGITAL EDITION BONUS CONTENT
DIGITAL EDITION BONUS CONTENT Denise Myshko Forecasting Pharma s Future Given the volatility of today s financial landscape, c ompanies, more than ever, need a robust forecasting strategy that is clear,
More informationVALUE-BASED HEALTHCARE A MANUFACTURER S PERSPECTIVE PETER JUHN, MD, MPH VICE PRESIDENT AND GLOBAL HEAD, VALUE-BASED PARTNERSHIPS
VALUE-BASED HEALTHCARE A MANUFACTURER S PERSPECTIVE PETER JUHN, MD, MPH VICE PRESIDENT AND GLOBAL HEAD, VALUE-BASED PARTNERSHIPS NATIONAL CONFERENCE OF STATE LEGISLATURES SAN DIEGO, CA DECEMBER 10, 2017
More informationCBI 13th Annual Commercial Contract & Chargeback Excellence. Parsippany, NJ June 21-22, 2017
CBI 13th Annual Commercial Contract & Chargeback Excellence Parsippany, NJ June 21-22, 2017 Changing Dynamics Impacting the Commercial Pricing and Contracting Landscape 13 th Annual Commercial Contract
More informationHEALTH POLICY AND DRUG PRICING: A RESEARCHER S PERSPECTIVE
HEALTH POLICY AND DRUG PRICING: A RESEARCHER S PERSPECTIVE NATASHA KEKRE, MD, MPH, FRCPC NOV 16, 2016 www.ohri.ca WHY THIS MATTERS TO ME I am a hematologist in Ottawa with 75% dedicated time for research
More informationMaximize the Collection of Real- World Data in Expanded Access Programs
Maximize the Collection of Real- World Data in Expanded Access Programs Jose Ricardo Perez, MD. Executive Medical Director Novartis Oncology East Hanover, NJ Disclaimer: The opinions expressed in this
More informationIntroduction to Pharmacogenomics. Outline
Introduction to Pharmacogenomics Grace M. Kuo, PharmD, MPH Associate Professor of Clinical Pharmacy Associate Adjunct Professor of Family & Preventive Medicine 1 Outline What is Pharmacogenomics? PharmGenEd
More information1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Drug Discovery and Development Market in Asia - Introduction 3 Drug Discovery and
1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Drug Discovery and Development Market in Asia - Introduction 3 Drug Discovery and Development Market in Asia - Overview 3.1 Introduction 3.1.1
More informationBiosimilars are interchangeable with their reference products under the supervision of a health care person.
EXTENDING THE USE OF BIOSIMILAR DRUGS: ARE WE WILLING TO ACCEPT THE UNCERTAINTY RELATED TO SWITCHING IN ORDER TO IMPROVE PATIENT ACCESS TO MODERN MEDICINES? Tomas Tesar, PharmD, PhD, MBA, MSc Member of
More informationLife Science Challenges and Opportunities in Latin America
Life Science Challenges and Opportunities in Latin America Roy Bateman, Trifermed Latin America One Nucleus Meeting, 29 January 2014 Overview of Latin America Basic facts, healthcare issues and the Pharmaceutical
More informationWho We Are. 1,000,000 The number of PAs adjudicated by our team in The percent of our employees who are clinically-degreed and certified.
Who We Are 4 Decades of Expertise Prior Authorization Pharmacy Data Analysis Clinical Advisory Services Who We Serve Self-Funded Employers Labor Funds Health Plans with members in Commercial, Medicare
More informationEthical approaches to Innovation in Global Health
Georg Marckmann Institute of Ethics, History and Theory of Medicine Ethical approaches to Innovation in Global Health World Health Summit Satellite Event Innovation in Health: The contribution of biologic
More informationNew Complexities in Pricing Orphan and Ultra-Orphan Drugs
New Complexities in Pricing Orphan and Ultra-Orphan Drugs September 28, 2010 Agenda Orphan drugs and their prices are less rare Changes in ultra-orphan markets Increased competition Big pharma enters When
More informationCross-National Effects of Pharmaceutical Pricing Policies. Patricia M. Danzon PhD The Wharton School University of Pennsylvania
Cross-National Effects of Pharmaceutical Pricing Policies Patricia M. Danzon PhD The Wharton School University of Pennsylvania Implications of Globalization for Pricing of Pharmaceuticals Pharmaceuticals
More informationCanada s Patented Medicine Prices Review Board. Michelle Boudreau, Executive Director Market Access Summit November 15-16, 2011
Canada s Patented Medicine Prices Review Board Michelle Boudreau, Executive Director Market Access Summit November 15-16, 2011 Overview Overview of the PMPRB Price Regulation Regime Observations of the
More informationCortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly
Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly May 14, 2015 Goteborg, Sweden and Trevose, Pa., USA and Victoria, Australia Cortendo AB (publ) [ticker: CORT
More informationCONTRACT RESEARCH SERVICES
1537 NW 65th Avenue Plantation, FL 33313 USA Phone: (954) 321-8988 Fax: (954) 321-9778 info@receptopharm.com www.receptopharm.com ReceptoPharm has installed the pathways to develop, produce and supply
More informationPharmaceutical Prices: International Issues
Pharmaceutical Prices: International Issues Patricia M. Danzon The Wharton School University of Pennsylvania Presented at National Health Policy Forum Session, Pharmaceutical Marketplace Dynamics, May
More informationBiosimilars 2016 Balancing Fast Uptake with Industry Sustainability. Dan Ionescu Head of Pricing and Market Access Sandoz Biopharmaceuticals
Biosimilars 2016 Balancing Fast Uptake with Industry Sustainability Dan Ionescu Head of Pricing and Market Access Sandoz Biopharmaceuticals 10 years on, biosimilars have had a strong impact on global healthcare
More information